GLP-1 Drugs Breaking Boundaries: Beyond Diabetes and Obesity Glucagon-like peptide 1 (GLP-1) therapies are not just for diabetes and obesity anymorethey are rewriting the rules of modern medicine
Weight loss across this period was stratified by quartiles of engagement (Quartiles of average total app opens at 40 weeks: Q1 = 244.7 , Q4 = 2,162.2)
These findings support its promise as an adjuvant medication in controlling and managing inflammatory bowel diseases
Dong, Y., Zhou, Y., Ding, Y., et al
Stress and Other Negative Emotions Emotional dysregulation also makes it difficult to handle stress
Series 1: obese C57BL/6J mice (high-fat diet) randomized to daily injections of hGH, AOD-9604, or placebo